Affiliation of Author(s):[1]Department of Pharmacy,Personalized Drug Therapy Key Laboratory of Sichuan Province,Sichuan Provincial People’s Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;[2]Sichuan Provincial Key Laboratory for Human Disease Gene Study and Department of Laboratory Medicine,Sichuan Provincial People’s Hospital,University of Electronic Science and Technology of China,Chengdu 610072,China;[3]Health Management Center,Sichuan Provincial People’s Hospital,University of Electronic Science and Technology of China,Chengdu 610072,China;[4]Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences(2019RU026),Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital,Chengdu 610072,China;[5]Department of Pharmacy,Jianyang People’s Hospital of Sichuan Province,Jianyang 641400,China
Journal:亚洲药物制剂科学（英文）
Key Words:Small interfering RNA;Tumor microenvironment;siRNA delivery;Cancer therapy;Co-delivery
Abstract:How to effectively transform the pro-oncogenic tumor microenvironments(TME)surrounding a tumor into an anti-tumoral never fails to attract people to study.Small interfering RNA(siRNA)is considered one of the most noteworthy research directions that can regulate gene expression following a process known as RNA interference(RNAi).The research about siRNA delivery targeting tumor cells and TME has been on the rise in recent years.Using siRNA drugs to silence critical proteins in TME was one of the most efficient solutions.However,the manufacture of a siRNA delivery system faces three major obstacles,i.e.,appropriate cargo protection,accurately targeted delivery,and site-specific cargo release.In the following review,we summarized the pharmacological actions of siRNA drugs in remolding TME.In addition,the delivery strategies of siRNA drugs and combination therapy with siRNA drugs to remodel TME are thoroughly discussed.In the meanwhile,the most recent advancements in the development of all clinically investigated and commercialized siRNA delivery technologies are also presented.Ultimately,we propose that nanoparticle drug delivery siRNA may be the future research focus of oncogene therapy.This summary offers a thorough analysis and roadmap for general readers working in the field.
Volume:18
Issue:5
Page Number:51-76
ISSN No.:1818-0876
Translation or Not:no
CN No.:21-1608/R